trending Market Intelligence /marketintelligence/en/news-insights/trending/nw8jrntapveptqopm2q-kw2 content esgSubNav
In This List

Editas Medicine appoints former Patheon CEO as chairman

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Editas Medicine appoints former Patheon CEO as chairman

Editas Medicine, Inc. appointed James Mullen as board chairman, effective March 28.

Mullen previously served as CEO of Patheon NV until the company's acquisition by Thermo Fisher Scientific Inc.

In addition, the Cambridge, Mass.-based biotechnology company said its co-founder Alexis Borisy and John Mendlein stepped down from the company's board.

Borisy joined the board in 2013. Mendlein, who is Moderna Therapeutics Inc.'s president of corporate and product strategy, joined Editas' board in 2016.